Gilead Sciences and Arcus Biosciences signed a 10-year partnership deal to co-develop and co-commercialize a number of Arcus’ pipeline products.
The U.S. Food and Drug Administration granted approval to Seattle Genetics Inc.’s Tukysa tablets in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Atomwise, a leader in using artificial intelligence for small-molecule discovery, and Bridge Biotherapeutics, a clinical-stage biotech company, announced a research collaboration to launch up to 13 small-molecule programs across multiple therapeutic areas using structure-based AI technology for drug discovery.
Stuart Hughes was named CEO of Pathios Therapeutics Ltd.
A new business direction was approved by the board of directors for Lund, Sweden-based Active Biotech.
Acceleron Pharma and Fulcrum Therapeutics enter 2020 as partners to tackle pulmonary diseases.
Bayer announced a three-year collaboration agreement with Children’s Hospital of Philadelphia (CHOP) for the discovery and development of small molecules to develop a first-in-class oral non-replacement therapy for the treatment of hemophilia A and B.
Dublin, Ireland-based Alkermes is acquiring Boston-based Rodin Therapeutics for $100 million up front and up to $850 million in milestone payments.
GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and the company’s transglutaminase 2 small molecule program for celiac disease.
Jazz Pharmaceuticals plc announced the acquisition of clinical-stage biotechnology company Cavion Inc. through a merger with a Jazz subsidiary.
